COMPANY

Metaclipse Therapeutics Corp.

HQ: Atlanta, GA source · metaclipse.com ↗ · Southeast

Keywords: vaccine oncology triple negative breast cancer triple-negative breast cancer head and neck squamous cell carcinoma

Location: Atlanta, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

11NIH grants

Timeline

Sep 5, 2025 Grant Government grant — NIH N43: $354,957 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Funding

Last 2 years.

Sep 5, 2025 Government grant — NIH N43: $354,957 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗

NIH awards 11

Annual award amounts. Total $8.5M.

Aug 29, 2022 NIH award 3R44CA257278-02S1 FY2022: $59,382 awarded for that fiscal year; activity R44 (SBIR); PI PACK, CHRISTOPHER D; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Clinical Evaluation of a source ↗
Aug 19, 2022 NIH award 5R44CA257278-02 FY2022: $938,597 awarded for that fiscal year; activity R44 (SBIR); PI PACK, CHRISTOPHER D; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Clinical Evaluation of a P source ↗
Apr 28, 2022 NIH award 3R44CA257278-01A1S1 FY2022: $34,640 awarded for that fiscal year; activity R44 (SBIR); PI PACK, CHRISTOPHER D; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Clinical Evaluation of source ↗
Sep 16, 2021 NIH award 1R44CA257278-01A1 FY2021: $1,061,403 awarded for that fiscal year; activity R44 (SBIR); PI PACK, CHRISTOPHER D; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Clinical Evaluation of source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93019C00017-P00003-9999-2 FY2020: $2,199,976 awarded for that fiscal year; activity N44 (OTHER_NIH); PI PACK, CHRISTOPHER; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, source ↗
Feb 6, 2019 NIH award 3R44CA221559-02S1 FY2019: $80,133 awarded for that fiscal year; activity R44 (SBIR); PI KANNAN, KAMAL V.; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. IND enabling studies for a p source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N93019C00017-0-9999-1 FY2019: $1,948,234 awarded for that fiscal year; activity N44 (OTHER_NIH); PI PACK, CHRISTOPHER; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLA source ↗
Jul 31, 2018 NIH award 5R44CA221559-02 FY2018: $1,079,344 awarded for that fiscal year; activity R44 (SBIR); PI KANNAN, KAMAL V.; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Membrane-based vaccine with source ↗
Sep 25, 2017 NIH award 1R44CA221559-01 FY2017: $700,539 awarded for that fiscal year; activity R44 (SBIR); PI KANNAN, KAMAL V.; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. Membrane-based vaccine with c source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 272201700062C-0-0-1 FY2017: $230,270 awarded for that fiscal year; activity N43 (OTHER_NIH); PI PACK, CHRISTOPHER; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, G source ↗
Aug 21, 2013 NIH award 1R43CA176920-01 FY2013: $144,759 awarded for that fiscal year; activity R43 (SBIR); PI PACK, CHRISTOPHER D; recipient as written: METACLIPSE THERAPEUTICS CORPORATION, ATLANTA, GA. A membrane-based immunothe source ↗